Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Rating of “Buy” from Analysts

Palvella Therapeutics, Inc. (NASDAQ:PVLA) has been assigned an average rating of “Buy” from the fifteen ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, twelve have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $209.1429.

A number of research analysts have weighed in on PVLA shares. Wall Street Zen lowered Palvella Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Truist Financial set a $207.00 target price on shares of Palvella Therapeutics in a research report on Wednesday. HC Wainwright reissued a “buy” rating and issued a $270.00 price target on shares of Palvella Therapeutics in a research note on Wednesday, July 22nd. Canaccord Genuity Group set a $232.00 price target on shares of Palvella Therapeutics in a research report on Wednesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Monday, June 29th.

Insiders Place Their Bets

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $110.73, for a total value of $476,360.46. Following the completion of the sale, the chief operating officer directly owned 2,154 shares in the company, valued at $238,512.42. This represents a 66.64% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 17.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Group One Trading LLC lifted its holdings in Palvella Therapeutics by 151.5% in the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after acquiring an additional 200 shares during the last quarter. KBC Group NV acquired a new stake in Palvella Therapeutics during the first quarter worth $28,000. Price T Rowe Associates Inc. MD increased its stake in Palvella Therapeutics by 11.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,090 shares of the company’s stock worth $429,000 after acquiring an additional 433 shares during the last quarter. Bank of America Corp DE increased its stake in Palvella Therapeutics by 12.3% during the third quarter. Bank of America Corp DE now owns 4,689 shares of the company’s stock worth $294,000 after acquiring an additional 515 shares during the last quarter. Finally, Deutsche Bank AG raised its position in Palvella Therapeutics by 8.7% in the fourth quarter. Deutsche Bank AG now owns 6,594 shares of the company’s stock valued at $690,000 after purchasing an additional 528 shares during the period. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Price Performance

NASDAQ PVLA opened at $154.93 on Friday. The company has a market cap of $2.23 billion, a PE ratio of -32.08 and a beta of -0.17. The stock’s 50 day simple moving average is $132.97 and its 200-day simple moving average is $119.75. Palvella Therapeutics has a 1-year low of $37.33 and a 1-year high of $161.38.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($1.52) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.35). On average, equities research analysts anticipate that Palvella Therapeutics will post -5.58 EPS for the current fiscal year.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical?stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small?molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil? and complement?mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.